Compile Data Set for Download or QSAR
Report error Found 82 Enz. Inhib. hit(s) with all data for entry = 1076
TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307593(US10150751, Example 31)
Affinity DataIC50: 11.2nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307575(US10150751, Example 9)
Affinity DataIC50: 13.6nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307600(US10150751, Example 38)
Affinity DataIC50: 14.6nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307577(US10150751, Example 12 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 15.3nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307583(US10150751, Example 19 | 2-(((3R,5R)-1-(2-(2H-1,2,...)
Affinity DataIC50: 22.9nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307579(US10150751, Example 15 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 23.1nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307598(US10150751, Example 36)
Affinity DataIC50: 23.6nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307587(US10150751, Example 24)
Affinity DataIC50: 23.9nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307578(US10150751, Example 14 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 26.3nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307594(US10150751, Example 32)
Affinity DataIC50: 29.7nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307592(US10150751, Example 30 | 2-(((3R,5R)-5-Methyl-1-(2...)
Affinity DataIC50: 31.1nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307595(US10150751, Example 33)
Affinity DataIC50: 31.1nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307585(US10150751, Example 21 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 31.5nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307588(US10150751, Example 25)
Affinity DataIC50: 36.1nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307584(US10150751, Example 20)
Affinity DataIC50: 39.8nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307601(US10150751, Example 39)
Affinity DataIC50: 40.8nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307608(US10150751, Example 47 | ((2S,4S)-4-((4-methoxypyr...)
Affinity DataIC50: 41nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307568(US10150751, Example 1)
Affinity DataIC50: 58.3nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307569(US10150751, Example 2 | 1-(2-((2R,4R)-4-((4-(2,2- ...)
Affinity DataIC50: 65.1nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307596(US10150751, Example 34 | Methyl 2-(((3R,5R)-1-(2-(...)
Affinity DataIC50: 66.2nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307589(US10150751, Example 27)
Affinity DataIC50: 67.8nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307580(US10150751, Example 16 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 75.9nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307590(US10150751, Example 28 | (4-(2H-1,2,3-triazol-2- y...)
Affinity DataIC50: 102nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307581(US10150751, Example 17 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 119nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307586(US10150751, Example 23)
Affinity DataIC50: 120nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307597(US10150751, Example 35)
Affinity DataIC50: 136nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307582(US10150751, Example 18 | 2-(((3R,5R)-1-(2-(2H-1,2,...)
Affinity DataIC50: 167nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307576(US10150751, Example 11 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 175nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307607(US10150751, Example 46 | ((2R,4R)-4-((4-Methoxypyr...)
Affinity DataIC50: 179nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307577(US10150751, Example 12 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 257nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307606(US10150751, Example 45 | ((2R,4R)-4-((4-Methoxypyr...)
Affinity DataIC50: 278nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307591(US10150751, Example 29)
Affinity DataIC50: 302nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307570(US10150751, Example 3 | (2-(2H-tetrazol-2-yl)pheny...)
Affinity DataIC50: 367nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307603(US10150751, Example 42 | ((2R,4R)-4-((3-Methoxypyr...)
Affinity DataIC50: 500nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307571(US10150751, Example 4 | (2-(2H-1,2,3-triazol-2-yl)...)
Affinity DataIC50: 520nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307572(US10150751, Example 5 | ((2R,4R)-4-((4-(2,2- diflu...)
Affinity DataIC50: 625nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307602(US10150751, Example 41 | ((2R,4R)-4-((3-Methoxypyr...)
Affinity DataIC50: 758nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307573(US10150751, Example 6 | ((2R,4R)-4-((4-(2,2- diflu...)
Affinity DataIC50: 989nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307578(US10150751, Example 14 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 1.09E+3nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307593(US10150751, Example 31)
Affinity DataIC50: 1.15E+3nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307579(US10150751, Example 15 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 1.16E+3nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307604(US10150751, Example 43 | (3-(1H-Pyrazol-1-yl)pyraz...)
Affinity DataIC50: 1.50E+3nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307600(US10150751, Example 38)
Affinity DataIC50: 1.55E+3nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307575(US10150751, Example 9)
Affinity DataIC50: 1.63E+3nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307574(US10150751, Example 7 | ((2R,4R)-4-((4-(2,2- diflu...)
Affinity DataIC50: 2.00E+3nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307597(US10150751, Example 35)
Affinity DataIC50: 2.25E+3nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307605(US10150751, Example 44 | ((2R,4R)-4-((3-Methoxypyr...)
Affinity DataIC50: 2.37E+3nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307587(US10150751, Example 24)
Affinity DataIC50: 2.72E+3nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307584(US10150751, Example 20)
Affinity DataIC50: 2.80E+3nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM307599(US10150751, Example 37)
Affinity DataIC50: 3.21E+3nMAssay Description: All reagents were from GIBCO-Invitrogen Corp. The seeded plates are incubated overnight at 37° C. and 5% CO2. Ala-6,12 human orexin-A as the agonist...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/31/2019
Entry Details
US Patent

Displayed 1 to 50 (of 82 total ) | Next | Last >>
Jump to: